| Range: | 8.79-42.2 | Vol Avg: | 1680118 | Last Div: | 0 | Changes: | -5.7 |
| Beta: | -0.58 | Cap: | 1.27B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jul 14 2000 | Empoloyees: | 29 | ||
| CUSIP: | 14817C107 | CIK: | 0001069530 | ISIN: | US14817C1071 | Country: | US |
| CEO: | Mr. Eric J. Schoen | Website: | https://www.cassavasciences.com | ||||
SAVA 26.65 Stock Price Cassava Sciences, Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Stock Details
Positive 0.56
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
Ms. Nassif brings an extensive track record of successfully developing commercial strategi...
globenewswire.com·Mon Nov 18 2024
Positive 0.39
What Makes Cassava Sciences (SAVA) a New Buy Stock
Cassava Sciences (SAVA) might move higher on growing optimism about its earnings prospects...
zacks.com·Tue Nov 12 2024
Positive 0.34
Cassava Sciences, Inc. (SAVA) Q3 2024 Earnings Call Transcript
Cassava Sciences, Inc. (NASDAQ:SAVA ) Q3 2024 Earnings Conference Call November 7, 2024 8:...
seekingalpha.com·Thu Nov 07 2024
Positive 0.23
Cassava Sciences Reports Q3 2024 Financial and Operating Results
AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a ...
globenewswire.com·Thu Nov 07 2024
Neutral 0.10
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a ...
globenewswire.com·Thu Oct 31 2024
Neutral 0.08
Analysts Believe Cassava Sciences Now Has 300% Upside From Here
Cassava Sciences Inc. NASDAQ: SAVA is a biotech developing treatments for Alzheimer's dise...
marketbeat.com·Wed Oct 30 2024
Positive 0.44
Why Cassava Sciences Stock Dived by Almost 11% Today
The biotech is paying $40 million not to acquire a drug or fund a development program, but...
fool.com·Fri Sep 27 2024
Neutral -0.06
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
Cassava Sciences (SAVA) shares dropped more than 11% after the company agreed to a $40 mil...
investopedia.com·Fri Sep 27 2024
Negative -0.23
Cassava Sciences settles SEC charges of ‘misleading' Alzheimer's trial claims
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday aft...
marketwatch.com·Thu Sep 26 2024
Negative -0.14
Cassava Sciences Resolves SEC Investigation
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the...
globenewswire.com·Thu Sep 26 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow